The company has secured $100 million upfront – with the remaining $160 million due if the erosive oesophagitis approval comes through – from Sagard Healthcare Partners, NovaQuest Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback